Post-translational regulated and hypoxia-responsible VEGF plasmid for efficient secretion

Area of Science:

• Cardiovascular Research
• Gene Therapy
• Molecular Biology

Background:

• Myocardial ischemia treatment faces challenges with non-specific gene expression.
• Angiogenic gene therapy offers promise but carries risks like tumor growth.
• Regulating gene expression is key to improving safety and efficacy.

Purpose of the Study:

• To engineer a hypoxia-inducible plasmid for controlled vascular endothelial growth factor (VEGF) expression.
• To enhance VEGF stability and secretion specifically under hypoxic conditions.
• To develop a safer and more effective gene therapy for myocardial ischemia.

Main Methods:

• Constructed a plasmid (pβ-SP-ODD-VEGF) with VEGF, an oxygen-dependent degradation (ODD) domain, and a secretion signal peptide (SP).
• Incorporated a furin recognition site to facilitate cleavage of the ODD-VEGF fusion protein.
• Assessed protein expression and secretion under hypoxic versus normoxic conditions.
• Investigated the role of furin in VEGF secretion using a furin inhibitor.

Main Results:

• The pβ-SP-ODD-VEGF plasmid showed increased SP-ODD-VEGF expression under hypoxia.
• Furin digestion was confirmed to enhance the secretion of VEGF.
• Secreted wild-type VEGF promoted endothelial cell growth more effectively under hypoxia.
• The engineered system demonstrated hypoxia-specific stabilization and secretion of VEGF.

Conclusions:

• The developed plasmid (pβ-SP-ODD-VEGF) represents a promising hypoxia-inducible gene therapy strategy.
• This approach offers improved control over VEGF delivery for myocardial ischemia treatment.
• Further research is warranted to explore its therapeutic potential in myocardial ischemia.